Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has officially announced that it is withdrawing its bid to buy generic pharmaceuticals rival Mylan N.V. after agreeing to buy Allergan Generics for $40.5 billion. This leaves Teva with a 4.6% stake in Mylan, which it bought for about $1.6 billion, as part of its hostile takeover bid…
For the full story, click here
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Published by Globes [online], Israel business news – www.globes-online.com